Johnson & Johnson spread its root into India 70 years ago.

Since then, the

company has brought many innovative ideas, products and services to
improve the health and well-being of people in India. The company today
employs more than 3,500 people and is organized into three business

1947
Johnson & Johnson Spreads Its Roots to India
1957
Johnson & Johnson Is Incorporated in India
 1959
The First Manufacturing Facility for Consumer
Products Is Established in Mumbai.
 1962
The First Medical Devices (Sutures) Manufacturing
Facility Is Established
 1968
Johnson & Johnson Begins Manufacturing Sanitary
Napkins
1975
A Pharmaceutical and Ethical Products Manufacturing
Facility Is Established
 1975
Vicryl® Sutures Enter the Market
 1989
The Ethicon Plant Receives the President’s Safety
Award

 1993
The First Professional Education Institute for
Healthcare Professionals Is Established
 1998
DePuy Joins the Johnson & Johnson Family of
Companies
 1999
An Analytical and Pharmaceutical Development R&D
Center Opens
 2009
The Company Begins Partnering With the Indian
Academy of Pediatrics to Support Child Survival
 2013
 Construction Begins on a New Manufacturing Facility
for Consumer Products
 2015
The Company Launches a New Class of Type 2
Diabetes Medicine in India
 2015
The Company Partners With NIPER for a Medical
Device Postgraduate Program
 2016
Global Clinical Operations Are Established in india
The Company Establishes an Innovative Partnership
With the Government of India on MDR-TB
 2017
The Company Supports the Humana People to People
Project, Designed to Save and Improve the Lives of
Women and Children
 2018
Johnson & Johnson India Joins Forces with the
Government of Maharashtra to Boost Public Health in
the State
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer
packaged goods manufacturing company founded in 1886. Its common stock is a component of
the Dow Jones Industrial Average and the company is ranked No. 37 on the 2018 Fortune 500 list of
the largest United States corporations by total revenue.
Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being
located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with
operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had
worldwide sales of $70.1 billion during calendar year 2015.[3] Johnson & Johnson's brands include
numerous household names of medications and first aid supplies. Among its well-known consumer
products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's
baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact
lenses.

J&J headquarters at One Johnson & Johnson Plaza in New

Brunswick, New Jersey

Type Public

Traded as NYSE: JNJ

DJIA Component
S&P 100 Component
S&P 500 Component

ISIN US4781601046

Industry Medical equipment

Pharmaceutical

Founded January 1886; 132 years ago

New Brunswick, New Jersey, United
States

Founders Robert Wood Johnson I

James Wood Johnson
Edward Mead Johnson

Headquarters One Johnson & Johnson Plaza,

New Brunswick, New Jersey

U.S.
 Area served Worldwide

Key people Alex Gorsky (Chairman andCEO)

Joe Wolk (CFO)

Products See list of Johnson & Johnson

products

Revenue US$76.450 billion (2017)[1]

Operating income US$17.673 billion (2017)[1]

Net income US$1.300 billion (2017)[1]

Total assets US$157.303 billion (2017)[1]

Total equity US$60.160 billion (2017)[1]

Number of 134,000 (2017)[1]

employees

Subsidiaries McNeil Consumer Healthcare

Vistakon[2]
Neutrogena
DePuy

Website www.jnj.com

Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer
packaged goods manufacturing company founded in 1886. Its common stock is a component of
the Dow Jones Industrial Average and the company is ranked No. 37 on the 2018 Fortune 500 list of
the largest United States corporations by total revenue.
ohnson & Johnson operates over 250 companies in what is termed "the Johnson & Johnson family
of companies".[4] The company operates in three broad divisions; Consumer Healthcare, Medical
Devices and Pharmaceuticals.
 Consumer Healthcare[5]

Baby Care
Skin & Hair Care
Wound Care and Topicals
Oral Health Care
Women's Health
McNeil Consumer Healthcare
Over-The-Counter Medicines
Nutritionals

Finance[edit]
For the fiscal year 2017, Johnson & Johnson reported earnings of US$1.3 billion, with an annual
revenue of US$76.5 billion, an increase of 6.3% over the previous fiscal cycle. Johnson & Johnson's
shares traded at over $126 per share, and its market capitalization was valued at over US$367.5
billion in September 2018.[80]

Revenue Net income Price per Share

Year Employees
in mil. US$ in mil. US$ in US$

2005 50,514 10,060 44.24

2006 53,324 11,053 43.48

2007 61,095 10,576 45.80

2008 63,747 12,949 47.70

2009 61,897 12,266 43.84

2010 61,587 13,334 48.70

2011 65,030 9,672 51.60

2012 67,224 10,853 56.37

2013 71,312 13,831 74.70 128,100

2014 74,331 16,323 90.34 126,500

2015 70,074 15,409 91.89 127,100

2016 71,890 16,540 107.77 126,400

2017 76,450 1,300 126.38 134,000

Johnsons Baby Product Price List India: (Upto 70% Off) Offers + 6% Cashback | Best
Discounts
Johnson & Johnsons Cashback
Johnson & Johnsons Models
Offers (Rs.)
Johnson's Baby Skincare Wipes(20
Rs. 66 5
Pieces)
Johnsons Milk Baby Lotion, 200 ml Rs. 128 35
Johnsons Baby Powder, 400 gm Rs. 62 35
Johnsons Baby Hair Oil, 200 ml Rs. 102 35
problem

Johnson & Johnson (NYSE:JNJ) shareholders can't complain too much about the stock's
performance in 2016. However, there's certainly room for improvement when a member of
the S&P 500 (SNPINDEX:^GSPC) trails the broader index's results -- as J&J did this year. Will
2017 bring more success for the healthcare giant? Perhaps, but Johnson & Johnson must navigate
these three major risks.
Remicade biosimilar
One quite worrisome risk ahead of Johnson & Johnson is Pfizer's (NYSE:PFE) launch of a
biosimilar to Remicade. The autoimmune disease drug is by far J&J's biggest moneymaker in its
pharmaceutical lineup, generating sales of over $5.3 billion in the first nine months of 2016.
The U.S. Food and Drug Administration (FDA) approved Celltrion's Remicade biosimilar,
Inflectra, in April. J&J has been trying to prevent the biosimilar from being marketed through
patent litigation. However, in August the U.S. District Court for the District of Massachusetts
ruled that a key J&J patent for Remicade was invalid.
Pfizer owns exclusive U.S. marketing rights to Inflectra. The big drugmaker launched the
biosimilar in late November. Although Johnson & Johnson continues to fight a legal battle to
take Inflectra off the market, there's no guarantee that it will win. Introduction of the Remicade
biosimilar in markets outside of the U.S. have already taken a bite out of J&J's sales.
Currency headwinds
Johnson & Johnson faced significant problems with currency fluctuations this year. During the
first nine months of 2016, the company reported year-over-year sales growth of 2.9%. Were it
not for the negative impact of currency fluctuations, that increase would have been 1.6% higher.
The problem this year wasn't in J&J's Asia Pacific and Africa regions, which didn't experience
any real currency headwinds. However, the currency impact was severe in the Americas
(excluding the U.S.), with an 11.7% negative impact on sales due to currency fluctuations. J&J
also felt the negative effects in Europe, where sales were 2.4% lower because of foreign
exchange rates.
It's impossible to know how significant the company's currency woes will be in 2017. There are
simply too many variables that impact exchange rates. Because of its significant international
presence, though, one thing is certain: Currency fluctuations will remain a key risk that could
hurt J&J's results.
Potential trade war with China
Speaking of that major international presence, there's another big risk that Johnson & Johnson
could face in 2017: a potential trade war with China. President-elect Donald Trump's phone call
with Taiwan president Tsai Ing-wen along with his tweets about China have raised concerns
about the prospects of a trade war.
Should the U.S. and China get into an economic battle by raising tariffs or changing trade
policies to the other nation's detriment, multinational companies, including Johnson & Johnson,
could feel the brunt of the dispute. Although J&J doesn't break out its results for China, the
company reported sales of $12.3 billion in 2015 from its Asia Pacific and Africa regions.
China has been important for several of J&J's products this year. In particular, the company
credited the launch of Zytiga in China earlier this year as a key factor behind solid sales growth
for the prostate cancer drug in the last quarter.
Riskiest risk
Of these three risks, I'd say the launch of the Remicade biosimilar is the scariest. If Pfizer is able
to take away significant market share, it would make a big financial impact on Johnson &
Johnson -- in 2017 and for years to come.
Currency fluctuations are just a cost that must be paid for doing business internationally. Some
years are worse than others. While J&J could experience more currency pain next year, it's not
something that investors would likely lose sleep over.
As for a potential trade war with China, who knows what will happen? A clash would hurt both
countries, so there's reason to hope that the current tensions will ease.
Even with all of these risks, however, Johnson & Johnson remains one of the steadier stocks on
the market. The company has been around for 130 years. It has racked up 32 consecutive years
of adjusted earnings increases and 54 consecutive years of dividend increases. We'll probably be
able to add a year to those totals in 2017.
Forget Netflix! This Next Gen Opportunity Could be 23X Bigger
When Netflix briefly passed Disney earlier this year to become the largest entertainment
company in the world, many analysts completely missed the point. Because Netflix could be just
the start of something much larger.
Just like AOL, Amazon and Netflix built their wealth off of the Internet, this “Next Gen”
opportunity is building its base off of the Internet, Netflix, Cable, and much more.
With PwC estimating media will be worth an estimated $2.2 trillion by 2021, and Netflix taking
home $11 billion in revenue last year, that leaves $2.189 trillion left over!
Income statement

USD FY, 2013 FY, 2014 FY, 2015 FY, 2016 FY, 2017

Revenue 71.3b 74.3b 70.1b 71.9b 76.5b

Revenue 4% (6%) 3% 6%
growth, %

Cost of goods 22.3b 22.7b 21.5b 21.7b 25.4b

sold

Gross profit 49.0b 51.6b 48.5b 50.2b 51.1b

Cash flow
USD FY, 2013 FY, 2014 FY, 2015 FY, 2016 FY, 2017

Net Income 13.8b 16.3b 15.4b 16.5b 1.3b

Depreciation 4.1b 3.9b 3.7b 3.8b 5.6b

and
Amortization

Inventories (622.0m) (1.1b) (449.0m) (249.0m) 581.0m

 USD FY, 2013 FY, 2014 FY, 2015 FY, 2016 FY, 2017

Accounts 1.8b 955.0m (3.0m) 656.0m 2.7b

Payable

COMPETETION IN THE MARKET

Johnson & Johnson (India), the pioneer in baby products in India, maintained its
dominance in the baby and child-specific products, with a 75% value share in 2011. The
company heavily benefits from the trust that it has built over the years and is
synonymous with baby care.

Smaller brands in Indian perspective, which includes Kimberly-Clark Lever’s Huggies

brand and Pigeon witnessed the biggest increase in value share in 2011. This can be
attributed to the rapid increase in demand for baby wipes by Huggies, driven by
growing baby health and hygiene awareness and exposure to international brands
amongst urban consumers.

International manufacturers such as Johnson & Johnson, with a long relation with the
Indian market continue to dominate the baby and child-specific products in 2011.
Domestic manufacturers, including The Himalaya Drug Co and Kräuter Healthcare,
aggressively launched new products in toiletries, and increased their market
capitalization rapidly.

Emami has launched a baby care product range including baby oil, baby shampoo and
baby powder in June 2012. The entire range of products is based on ayurvedic
ingredients, which outperformed overall baby care.

Interestingly the baby care market still relies on trust and word of mouth marketing and
no significant advertising campaigns were carried out for promotion with the exception
of Johnson & Johnson who organized awareness campaigns to educate consumers in
rural areas.

There was no significant change in packaging of baby and child-specific products. Most
children’s soaps continued to be attractively packaged in bright colors while other baby
care products continued to be sober-colored which gave them a gentle appearance.

Mass products continued to dominate the market. Indian consumers are very familiar
with mass brands such as Johnson’s Baby and Himalaya, and have successfully created a
relationship of trust with Indian families in terms of their quality. However, premium
baby care products, including products such as Pigeon, SebaMed, Garfield Baby India
from Zen Hygiene, have started to pick up gradually in urban areas such as Bangalore
and Mumbai.